Cardiff Oncology Inc [CRDF] stock is trading at $3.16, up 1.94%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRDF shares have gain 4.64% over the last week, with a monthly amount glided 1.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on June 24, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $3.50. Previously, Craig Hallum started tracking the stock with Buy rating on September 06, 2024, and set its price target to $8. On January 05, 2022, William Blair initiated with a Outperform rating. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $19 on December 08, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on October 22, 2020, and assigned it a price target of $27. In a note dated October 08, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $25 on this stock.
Cardiff Oncology Inc [CRDF] stock has fluctuated between $2.01 and $5.64 over the past year. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $3.16 at the most recent close of the market.
Analyzing the CRDF fundamentals
Cardiff Oncology Inc [NASDAQ:CRDF] reported sales of 0.59M for the trailing twelve months, which represents a drop of -46.83%. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -108.77%, Pretax Profit Margin comes in at -102.02%, and Net Profit Margin reading is -102.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -0.76 and Total Capital is -0.73. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.08 points at the first support level, and at 3.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.22, and for the 2nd resistance point, it is at 3.27.
Ratios To Look Out For
For context, Cardiff Oncology Inc’s Current Ratio is 6.22. On the other hand, the Quick Ratio is 6.22, and the Cash Ratio is 1.81. Considering the valuation of this stock, the price to sales ratio is 356.31, the price to book ratio is 2.97.
Transactions by insiders
Recent insider trading involved Levine James E., Chief Financial Officer, that happened on Dec 17 ’24 when 2752.0 shares were purchased. Chief Financial Officer, Levine James E. completed a deal on Dec 18 ’24 to buy 2400.0 shares. Meanwhile, Chief Financial Officer Levine James E. bought 2564.0 shares on Dec 16 ’24.
